Hence, tyrosine kinase inhibitors and immunotherapy can be effective lines treatment for advanced HCC and can give durable response duration, and probable radiological PR can be achieved with Nivolumab.Roy, ParagParthasarathy, K. M.Journal of Cancer Research & Therapeutics...
Mechanisms of off-target resistance to first- or second-generation TRK inhibitors include KRAS and BRAF V600E mutations, MET amplifications, IGF1R activation, etc. The convergent activation of mitogen-activated protein kinase (MAPK) pathway was also proposed to mediate the resistance of TRK inhibiti...
1C). In common with other tyrosine kinase fusion genes, Sptbn1-Flt3 is constitutively active and transforms Ba/F3 cells to IL-3 independence. We demonstrated that the SPTBN1-FLT3 transformed cell lines are a useful means to compare the potencies of different inhibitors and, in particular, ...
Table 1 Major differences between monoclonal antibodies and small molecule tyrosine kinase inhibitors. Full size table Monoclonal Antibodies Immunotherapy is based on the production of humanized monoclonal antibodies (mAbs) that bind with high specificity to secreted proteins or to the extracellular domain ...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. So, overcoming resistance of EGFR TKIs has become...
45,46 Thus, pharmacologic inhibition of the TCR and/or of its associated kinases using multi-tyrosine kinase inhibitors (TKIs) might represent a strategy to augment response rates and decrease chemotherapy resistance. Dasatinib, an orally administered well-tolerated small molecule inhibitor of multiple ...
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Tyrosine kinase inhibitors (TKIs) remain the backbone of systematic therapy for advanced hepatocellular carcinoma. Sorafenib and lenvatinib are currently approved as fi
3 However, it could also indicate that the CRAFITY score may be less helpful in predicting radiological response in patients receiving tyrosine kinase inhibitors (TKIs). This was observed in the original publication, where the score was only able to predict radiological outcome in immunotherapy-...
tyrosine kinase inhibitors (TKIs), target-specific inhibitors of PTKs, have been used in treating malignant tumors and play a significant role in targeted therapy of cancer. Currently, drug resistance is the main reason for limiting TKIs efficacy of cancer. The increasing studies indicated that tumo...
Genetic deletion of the RAC guanine nucleotide exchange factor (RacGEF) VAV3 inhibits leukemic cell survival in vitro and in vivo and sensitizes lymphoblastic leukemia cells to tyrosine kinase inhibitors (TKIs) [12]. In addition, despite tremendous success of TKIs in treating B-ALL in the clinic...